Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

ITRM Iterum Therapeutics plc

Price (delayed)

$0.986

Market cap

$39.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.95

Enterprise value

$38.07M

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people ...

Highlights
ITRM's quick ratio has surged by 155% since the previous quarter
ITRM's EPS has soared by 64% YoY and by 25% QoQ
ITRM's gross profit has plunged by 135% from the previous quarter

Key stats

What are the main financial stats of ITRM
Market
Shares outstanding
40M
Market cap
$39.44M
Enterprise value
$38.07M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
-$596,000
Operating income
-$16.24M
Net income
-$22.56M
EBIT
-$19.74M
EBITDA
-$19.12M
Free cash flow
-$16.75M
Per share
EPS
-$0.95
EPS diluted
-$0.95
Free cash flow per share
-$0.49
Book value per share
-$0.07
Revenue per share
$0
TBVPS
$0.4
Balance sheet
Total assets
$32.98M
Total liabilities
$35.53M
Debt
$11.32M
Equity
-$2.55M
Working capital
$9.89M
Liquidity
Debt to equity
-4.43
Current ratio
3.72
Quick ratio
3.5
Net debt/EBITDA
0.07
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-83.8%
Return on equity
N/A
Return on invested capital
-214.9%
Return on capital employed
-67.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ITRM stock price

How has the Iterum Therapeutics stock price performed over time
Intraday
6.2%
1 week
-3.33%
1 month
-6.1%
1 year
-33.38%
YTD
-44.29%
QTD
-19.84%

Financial performance

How have Iterum Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
-$596,000
Operating income
-$16.24M
Net income
-$22.56M
Gross margin
N/A
Net margin
N/A
ITRM's gross profit has plunged by 135% from the previous quarter
The operating income has surged by 64% year-on-year and by 13% since the previous quarter
The net income rose by 37% YoY and by 9% QoQ

Price vs fundamentals

How does ITRM's price correlate with its fundamentals

Growth

What is Iterum Therapeutics's growth rate over time

Valuation

What is Iterum Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ITRM's EPS has soared by 64% YoY and by 25% QoQ
Iterum Therapeutics's equity has surged by 58% YoY and by 37% QoQ

Efficiency

How efficient is Iterum Therapeutics business performance
The ROIC has dropped by 117% year-on-year and by 4.2% since the previous quarter
ITRM's ROA is up by 20% QoQ and by 20% YoY

Dividends

What is ITRM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ITRM.

Financial health

How did Iterum Therapeutics financials performed over time
The total assets is 7% smaller than the total liabilities
ITRM's current ratio has surged by 164% since the previous quarter
ITRM's quick ratio has surged by 155% since the previous quarter
Iterum Therapeutics's equity has surged by 58% YoY and by 37% QoQ
The debt has shrunk by 55% QoQ and by 44% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.